Literature DB >> 11114285

Intestinal permeability in Behçet's syndrome.

I Fresko1, V Hamuryudan, M Demir, N Hizli, H Sayman, M Melikoğlu, R Tunç, S Yurdakul, H Yazici.   

Abstract

OBJECTIVE: To measure the intestinal permeability in patients with Behçet's syndrome (BS) and to compare the results with those obtained from healthy and diseased controls.
METHOD: The study group comprised 34 patients with BS without known gastrointestinal disease. Ten patients with ankylosing spondylitis (AS), 6 with inflammatory bowel diseases (IBD), 17 with systemic lupus erythematosus (SLE), and 15 healthy subjects (HC) constituted the controls. All patients received 100 microCi (3.7 MBq) of chromium-51 EDTA ((51)Cr-EDTA) as a radioactive tracer after a 72 hour abstinence from all drugs. The percentage of the isotope excreted in a 24 hour urinary specimen was the measure of permeability.
RESULTS: The percentage (SD) rate of excretion of (51)Cr-EDTA was 4.6 (2.6) in BS, 6 (2.4) in AS, 5.2 (1. 9) in IBD, 5.56 (1.78) in SLE, and 2.3 (1) in healthy controls. (Analysis of variance: f=6.4, p=0.0002. BS v HC, AS v HC, SLE v HC significant.)
CONCLUSION: The intestinal permeability in BS was significantly more than that seen among the healthy controls. Similar results in all the diseased controls cast doubt on its specificity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11114285      PMCID: PMC1753363          DOI: 10.1136/ard.60.1.65

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?

Authors:  Zeki Yesilova; Salih Pay; Cagatay Oktenli; Ugur Musabak; Kenan Saglam; S Yavuz Sanisoglu; Kemal Dagalp; M Kemal Erbil; Ismail H Kocar
Journal:  Rheumatol Int       Date:  2004-04-01       Impact factor: 2.631

2.  Anti-Saccaromyces Cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid disease.

Authors:  Dilek Yazıcı; Sibel Zehra Aydın; Dilek Yavuz; Ozlem Tarçın; Oğuzhan Deyneli; Haner Direskeneli; Sema Akalın
Journal:  Endocrine       Date:  2010-07-16       Impact factor: 3.633

3.  Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis.

Authors:  Wahiba Sakly; Moncef Jeddi; Ibtissem Ghedira
Journal:  Dig Dis Sci       Date:  2007-11-30       Impact factor: 3.199

Review 4.  Gastrointestinal manifestations of Behçet's disease.

Authors:  Ellen C Ebert
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

5.  Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes.

Authors:  Wahiba Sakly; Amani Mankaï; Nabil Sakly; Yosra Thabet; Achouak Achour; Leila Ghedira-Besbes; Moncef Jeddi; Ibtissem Ghedira
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

6.  Clinical characteristics of concurrent and sequentially presented lupus-related protein-losing enteropathy: what are their differences?

Authors:  Siu-Tong Law; Kwok Man Ma; Kin Kong Li
Journal:  Rheumatol Int       Date:  2012-01-05       Impact factor: 2.631

7.  Anti-Saccharomyces cerevisiae antibodies in patients with systemic lupus erythematosus.

Authors:  Amani Mankaï; Wahiba Sakly; Yosra Thabet; Achouak Achour; Wiem Manoubi; Ibtissem Ghedira
Journal:  Rheumatol Int       Date:  2012-04-10       Impact factor: 2.631

8.  Increased sucrose permeability in Behçet's disease.

Authors:  Bayram Koc; Serdar Aymelek; Alper Sonmez; M Ilker Yilmaz; Hakki Kocar
Journal:  Rheumatol Int       Date:  2003-10-07       Impact factor: 2.631

9.  Using Multiple Analytical Platforms to Investigate the Androgen Depletion Effects on Fecal Metabolites in a Mouse Model of Systemic Lupus Erythematosus.

Authors:  Fang Yuan; James Harder; Jing Ma; Xinmin Yin; Xiang Zhang; Michele M Kosiewicz
Journal:  J Proteome Res       Date:  2019-12-27       Impact factor: 4.466

10.  Multiple transverse colonic perforations associated with slow-release nonsteroidal anti-inflammatory drugs and corticosteroids: a case report.

Authors:  Nobuki Shioya; Shigehiro Shibata; Masahiro Kojika; Shigeatsu Endo
Journal:  Case Rep Crit Care       Date:  2011-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.